Multicenter Retrospective Study on the Utilization of FEIBA in France in Patients with Factor VIII and Factor IX Inhibitors

Summary

Factor VIII or factor IX replacement is frequently impossible in inhibitor-developing hemophiliacs, because of the level of the inhibitor titer. Activated prothrombin complex concentrates are one of the available options to treat the bleeding episodes in such patients. However, the efficacy of these products and the associated thrombogenic risk, particularly in prolonged administration such as employed during surgeries, are important concerns for hemophilia care providers. We performed a multicenter retrospective study to evaluate the use of FEIBA (Factor Eight Bypassing Activity) in France, and data is presented on 433 bleeding episodes, including surgical procedures, concerning 60 patients from 15 hemophilia centers.

The efficacy was judged as good or excellent in 352 episodes (81.3%), poor in 73 episodes (16.9%) and non-existent in 8 episodes (1.8%). Minor and major surgical procedures were successfully performed using FEIBA as a second-line therapy after human or porcine factor VIII, and in some occasions FEIBA was utilized as the only substitution product. The tolerance was assessed as good in 428 episodes (98.8%), but in 5 cases adverse effects were reported. Only 3 patients out of 52 regularly evaluated (5.8%) were HIV-seropositive, and for two of them the seroconversion occurred prior to the first use of FEIBA. In contrast, 80.4% of the patients were HCV-seropositive. An anamnestic response after the administration of FEIBA was noted in 31.5% of cases. This study points out the main features of the use of FEIBA in France, and particularly the low HIV seroprevalence in the patients treated. The good efficacy and the excellent tolerance still confer to this product a place to consider in the therapeutic options for the treatment of inhibitor-developing hemophiliacs or in acquired hemophilia.

• References

• 1 Kasper CK. Treatment of factor VIII inhibitors. Prog Hemost Thromb 1989; 09: 57-86
• 2 Brettler DB, Forsberg AD, Levine PH, Buttler DB, Aledort LM, Hilgartner MW, Kasper CK, Lusher JM, McMillan C, Roberts H. The use of porcine factor VIII concentrate (HyateC) in the treatment of patients with inhibitor antibodies to factor VIII: A multicenter US experience. Arch Intern Med 1989; 149: 1381-1385
• 3 Hedner U, Glazer S, Pingel K, Alberts KA, Blombäck M, Schulman S, Johnsson H. Successful use of recombinant factor Vila in patient with severe hemophilia A during synovectomy. Lancet 1988; 02: 1193
• 4 Lusher JM, Shapiro SS, Palascak J. et al Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII. N Engl J Med 1980; 303: 421-425
• 5 Sjamsoedin LJM, Heijnen L, Mauser-Bunschoten EP, Van GeijlswijkJL, Van HouwelingenH, Van AstenP, Sixma JJ. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. N Engl J Med 1981; 305: 717-721
• 6 Lusher JM, Blatt PM, Penner JA, Aledort LM, Levine PH, White GC, Warrier Al, Whitehurst DA. Autoplex versus proplex: a controlled, doubleblind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII. Blood 1983; 62: 1135-1138
• 7 Slolombe GW, Newland AC, Colvin MP, Colvin BT. The role of intensive plasma exchange in the prevention and management of haemorrhage in patients with inhibitors to factor VIII. Br J Haematol 1981; 47: 577-585
• 8 Nilsson IM, Jonsson S, Sundqvist SB, Ahlberg A, Bergentz SE. A procedure for removing high titer antibodies by extracorporeal protein-A-sepha-rose adsorption in hemophilia: substitution therapy and surgery in a patient with hemophilia B and antibodies. Blood 1981; 58: 38-44
• 9 Abildgaard CF. Hazards of prothrombin-complex concentrates in treatment of hemophilia. N Engl J Med 1981; 304: 670-671
• 10 Lusher JM. Thrombogenicity associated with factor IX complex concentrates. Semin Hematol 1991; 28 (Suppl. 06) 03-05
• 11 Hilgartner M, Knatterud GL. and the FEIBA study group The use of Factor Eight By-passing Activity (FEIBA Immuno) product for treatment of bleeding episodes in haemophiliacs with inhibitor. Blood 1983; 61: 36-40
• 12 Hilgartner M, Aledort L, Andes A, Gill J. and the members of the FEIBA Study Group Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. Transfusion 1990; 30: 626-630
• 13 Kasper CK, Aledort LM, Counts RB, Edson JR, Fratantoni J, Green D, Hampton JW, Hilgartner MW, Lazerson J, Levine PH, McMillan CW, Pool JG, Shapiro SS, Schulman NR, Van EyeJ. A more uniform measurement of factor VIII inhibitors. Thromb Diathes Haemorrh 1975; 34: 869-872
• 14 Rizza CR, Biggs R. The treatment of patients who have factor VIII antibodies. Br J Haematol 1973; 24: 65-82
• 15 Sultan Y. and the French Haemophilia study group Prevalence of inhibitors in a population of 3435 hemophilic patients in France. Thromb Haemost 1992; 67: 600-602
• 16 Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Kogenate Previously Untreated Patient Study Group Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A: safety, efficacy, and development of inhibitor. N Engl J Med 1993; 328: 453-459
• 17 Bray GL, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, Shapiro A, Scheibel E, White III G, Lee M. and the Recombinate Study Group A multicenter study of recombinant factor VIII (Recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. Blood 1994; 83: 2428-2435
• 18 Negrier C, Dechavanne M, Lalain JJ, Delacroix P. Successful arthroscopic synovectomy using Holmium: Yag laser and FEIBA in a high responder hemophiliac. Am J Hematol 1993; 44: 74-75
• 19 Mizon P, Goudemand J, Jude B, Marey A. Myocardial infarction after FEIBA therapy in a hemophilia-B patient with a factor IX inhibitor. Ann Hematol 1992; 64: 309-311
• 20 Schimpf KL, Zeltsch CH, Zeltsch P. Myocardial infarction complicating activated prothrombin complex concentrate substitution in patient with hemophilia A. Lancet 1982; 2: 1043
• 21 Chavin SI, Siegel DM, Rocco TA, Olson JP. Acute myocardial infarction during treatment with an activated prothrombin complex concentrate in a patient with factor VIII deficiency and a factor VIII inhibitor. Am J Med 1988; 85: 245-249
• 22 Barrowcliffe TW, Kemball-Cook G, Gray E. Factor VIII inhibitor bypassing activity: a suggested mechanism of action. Thromb Res 1981; 21: 181-186
• 23 Mannucci PM, Gdovin S, Gringeri A, Colombo M, Mele A, Schinial N, Ciavarella N, Emerson SU, Purcell RH. and the Italian Collaborative Group Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group. Ann Intern Med 1994; 120: 01-07
• 24 Lefrère JJ, Mariotti M, Thauvin M. B19 parvovirus DNA in solvent/detergent-treated anti-hemophilia concentrates. Lancet 1994; 343: 211-212
• 25 Mannucci PM, Schimpf K, Abe T, Aledort L, Anderle K, Brettler D, Hilgartner M, Kernoff P, Kunaschk M, McMillan C, Preston F, Rivard G. and the International Investigator Group Low risk of viral infection after administration of vapor-heated factor VIII concentrate. Transfusion 1992; 32: 134-138
• 26 Gazengel C, Larrieu MJ. Lack of seroconversion for LAV/HTLV-III in patients exclusively given unheated activated prothrombin complex prepared with ethanol step. Lancet 1985; 2: 1189
• 27 Turecek PL, Schwarz HP, Barrett N, Pölsler G, Dorner F, Eibl J. FEIBA®VH Immuno: Partitioning and inactivation of HIV-1. In: LM Aledort. (ed) Proceedings of the second international symposium on inhibitors to coagulation factors. Plenum Publishing Corporation; 1995. p 297
• 28 Troisi CL, Hollinger FB, Hoots WK, Contant C, Gill J, Ragni M, Parmley R, Sexauer C, Gomperts E, Buchanan G, Schwartz B, Adair S, Fields H. A multicenter study of viral hepatitis in a United States hemophilic population. Blood 1993; 81: 412-418